Feb 04, 2013, 10.41 AM | Source: CNBC-TV18
Sudarshan Sukhani of s2analytics.com is of the view that one can buy Dr Reddys Laboratories.
Sudarshan Sukhani (more)
Technical Analyst, s2analytics.com | Capital Expertise: Equity - Technical
Sukhani told CNBC-TV18, " Dr Reddys Laboratories was in a small range. It is now inching upwards. Once it does that, once it gets little more follow-throughs, a little more push on the upside, it starts making lifetime new highs. These lifetime new highs is what we want to buy or even anticipated lifetime new highs are worth going when the stock is as strong as Dr Reddy’s."
He further added, "It is a short-term trade because pharmaceutical is looking tired like the Nifty but for short-term traders there is money on the upside. This is something that one can buy in the morning if one sees strength."
Canadian drug regulator Health Canada may soon all
Net Sales are expected to increase by 2.9 percent
Domestic pharmaceutical companies are likely to re
The drug, a therapeutic equivalent generic version
Dr Reddy's Laboratories has launched Aripiprazole